ImmunoGen, Inc. (IMGN) Director Daniel M. Junius Sells 46,667 Shares of Stock

ImmunoGen, Inc. (NASDAQ:IMGN) Director Daniel M. Junius sold 46,667 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $10.01, for a total transaction of $467,136.67. Following the sale, the director now directly owns 243,367 shares in the company, valued at $2,436,103.67. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of ImmunoGen, Inc. (NASDAQ:IMGN) traded up $0.35 during midday trading on Thursday, reaching $10.15. 2,414,600 shares of the company traded hands, compared to its average volume of 3,315,400. The company has a market capitalization of $1,340.00, a price-to-earnings ratio of -9.95 and a beta of 2.50. ImmunoGen, Inc. has a fifty-two week low of $2.40 and a fifty-two week high of $10.66. The company has a debt-to-equity ratio of -0.03, a quick ratio of 2.78 and a current ratio of 2.81.

ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, February 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The company had revenue of $39.40 million for the quarter, compared to analyst estimates of $39.62 million. The firm’s quarterly revenue was up 185.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.39) earnings per share. equities analysts anticipate that ImmunoGen, Inc. will post -1.04 EPS for the current year.

IMGN has been the topic of a number of research reports. Zacks Investment Research raised shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a report on Tuesday, October 31st. HC Wainwright started coverage on shares of ImmunoGen in a research note on Wednesday, January 31st. They issued a “buy” rating on the stock. BidaskClub raised shares of ImmunoGen from a “hold” rating to a “buy” rating in a research note on Thursday, January 18th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a research note on Friday, November 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of ImmunoGen in a research note on Thursday, February 8th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $9.10.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. raised its holdings in ImmunoGen by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 331,898 shares of the biotechnology company’s stock worth $2,360,000 after buying an additional 1,919 shares during the last quarter. TIAA CREF Investment Management LLC raised its holdings in ImmunoGen by 3.1% during the second quarter. TIAA CREF Investment Management LLC now owns 252,260 shares of the biotechnology company’s stock worth $1,794,000 after buying an additional 7,658 shares during the last quarter. Vanguard Group Inc. raised its holdings in ImmunoGen by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,248,688 shares of the biotechnology company’s stock worth $30,209,000 after buying an additional 138,257 shares during the last quarter. FMR LLC raised its holdings in ImmunoGen by 598.9% during the second quarter. FMR LLC now owns 5,605,285 shares of the biotechnology company’s stock worth $39,854,000 after buying an additional 4,803,256 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its holdings in ImmunoGen by 130.1% during the second quarter. Parametric Portfolio Associates LLC now owns 88,553 shares of the biotechnology company’s stock worth $630,000 after buying an additional 50,061 shares during the last quarter. 67.97% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “ImmunoGen, Inc. (IMGN) Director Daniel M. Junius Sells 46,667 Shares of Stock” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://weekherald.com/2018/02/15/immunogen-inc-imgn-director-daniel-m-junius-sells-46667-shares-of-stock.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply